Skip to main content
Log in

TNO-6 has no effect in gastrointestinal cancer:N-acetyl-glucosaminidase shows renal damage

  • Articles
  • Published:
Medical Oncology and Tumor Pharmacotherapy Aims and scope Submit manuscript

Abstract

Twenty-five patients, 16 with gastric cancer and nine with colonic cancer, received TNO-6 30 mg m−2 every four weeks. No objective tumour response was recorded. Nausea and vomiting occurred in 21 patients and was severe in 17. Severe marrow suppression developed in five patients. Renal function was unaffected in all but one patients who developed renal failure, probably as a result of septicaemia. However, the renal tubular enzymeN-acetyl-\-d-glucosaminidase was measured in six patients and showed a rise in all. In this study TNO-6 had no anti-tumour activity in gastrointestinal malignancy, but produced significant renal tubular damage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Leichman L, McDonald B, Dindogru A, Samson M, Vaitkevicius V K: Cisplatin: an active drug in the treatment of disseminated gastric cancer.Cancer 53, 18 (1984).

    Article  PubMed  CAS  Google Scholar 

  2. Lehane D E, Zubler M A, Lane M, Smith F E: Intra-arterial cisplatin in metastatic or recurrent colon cancer.Proceedings of the 18th Annual Meeting of the American Society of Clinical Oncology, April, p. 94 (1982).

  3. Lelieveld P, Atassi G, Van Putten L M: Preclinical toxicity studies of cisplatin and three currently developed analogues. Presented at the NII-EORTC Symposium on Nature, Prevention and Treatment of Clinical Toxicity of Anti-cancer Agents, Brussels, 25 September (1980).

  4. Pinedo H, Ten Bokkel Hiunink W, Simonetta G, Gall H, Van der Vijgh W, Canetta R, Van Putten L, Vermorken J, McVie G: Phase II study and pharmacokinetics ofcis-1, 1-di(aminomethyl)cyclohexane Pt II sulphate (TNO-6).Proceedings of ASCO, Vol. 1, March (1982).

  5. Pinedo H, Ten Bokkel Hiunink W, Gall H, McVie G, Simonetta G, Van der Vijgh W, Farber L, Vermorken J: Toxicity ofcis-1, 1di(aminomethyl)-cyclohexane platinum (Pt) II sulphate (TNO-6) in relation to method of administration.Proceedings of ASCO, March, p. 33 (1983).

  6. Miller A B, Hoogstraten B, Staquet M, Winker A: Reporting results of cancer treatment.Cancer 47, 207 (1981).

    Article  PubMed  CAS  Google Scholar 

  7. Cunningham D, Soukop M, McArdle C S, Carter D C, Smyth J F, Allan S G, Kaye S B, Sangster G, Calman K C, Hutcheon A W, Boyle P: Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C.Brit J Surg 71, 673 (1984).

    Article  PubMed  CAS  Google Scholar 

  8. Franks C R, Nys G, Materman, E, Uytdenhoef M, Canetta R, Lenaz L, Carter S K: TNO-6 (1,1-diamino-methylcyclohexane sulphate platinum II, NSC-311056) in phase II trials. InProceedings of the Fourth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Brussels (1983).

  9. Lockwood T D, Bossmann H B: The use of urinaryN-acetyl-\-glucosaminidase.Hum Renal Toxicity 49, 323 (1979).

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cunningham, D., Soukop, M., Gilchrist, N.L. et al. TNO-6 has no effect in gastrointestinal cancer:N-acetyl-glucosaminidase shows renal damage. Med. Oncol. & Tumor Pharmacother. 3, 25–28 (1986). https://doi.org/10.1007/BF02934572

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02934572

Key words

Navigation